180 seconds for the future of therapy for multi-morbid older people

In Europe, two thirds of people above 65 are suffering from multi-morbidity. This leads to polypharmacy and often to adverse drug events due to inappropriate prescribing. The European funded SENATOR project has therefore developed and tested a highly efficient software engine for the assessment and optimization of drug and non-drug therapy in multi-morbid older people.

Prof. Denis O´Mahony

Project coordinator, Prof. Denis O’Mahony (University College Cork, Ireland) explains why adverse drug events are strongly linked to multi-morbidity and how the SENATOR software addresses this problem.

Prof. Mirko Petrovic

Prof. Mirko Petrovic (Ghent University Hospital, Belgium) explains the relationship between multi-morbidity and adverse drug events through polypharmacy and shows perspectives for SENATOR and improved healthy ageing.

Prof. Antonio Cherubini

Prof. Antonio Cherubini (INRCA- Istituto Nazionale di Riposo e Cura per Anziani, Ancona) talks about the importance of non-drug therapies with regard to multi-morbid older people and their inclusion in the recommendations coming out from the SENATOR software in order to increase their usage in clinical care.

Prof. Joseph Eustace

Clinical research specialist Prof. Joseph Eustace (University College Cork, Ireland) talks about SENATOR clinical trial and the use of SENATOR software in clinical practice, his own experience with this tool and desired outcomes if once used as standardized method on a routine basis

Joseph McMullin

Joseph McMullin (ClanWilliam Health Ltd, Dublin) elaborates on the challenges of the development of the SENATOR software from a developer point of view and draws a conclusion with regard to the effectiveness of this tool.